Industries > Pharma > Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029

Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029

Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy

PUBLISHED: 06 June 2019
PAGES: 195
PRODUCT CODE: PHA0437
SUBMARKET:

Clear
WOOCS 2.2.1
SKU: PHA0437 Category: Tags: , , ,

The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 195-page report you will receive 131 tables and 66 figures– all unavailable elsewhere.

The 195-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029

• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Cancer Type:
• Lung Cancer
• Breast Cancer: HER-2 Positive, HR Positive, TNBC
• Colorectal Cancer
• Other Cancers

Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029

• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Biopsy Type:
• Tissue Biopsy
• Liquid Biopsy

• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Regional and National market:
• US
• Japan
• Germany
• France
• Italy
• UK
• Spain
• China
• India
• Brazil
• Russia

The forecast of each country is further broken down by cancer type and biopsy type.

• Profile of the selected leading companies:
• Abbott Laboratories
• Agilent Technologies, Inc.
• bioMerieux SA
• Genomic Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Qiagen N.V.
• Roche Holding AG
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

• Analysis of factors that drive and restrain the global precision cancer diagnostics tests market

• Key Questions Answered by this Report:
• How the global precision cancer diagnostic tests market is evolving?
• What are the drivers, restraints and opportunities in the global precision cancer diagnostic tests market?
• How will each of the sub-markets of the precision cancer diagnostic tests market develop over the period of study?
• Who are the leading players in the precision cancer diagnostic tests market and what are their future perspective during the period of study?
• What are the recent developments in the global precision cancer diagnostic tests market?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Precision Cancer Diagnostics Test Market. You find data, trends and predictions.

Buy our report today Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029


Latest Pharma news

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Visiongain Publishes Clinical Perinatal Software Market Report 2020-2030

Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.

01 July 2020

READ

Visiongain publishes Clinical Laboratory Tests Market Report 2020-2030

Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.

01 July 2020

READ

Categories

Category